This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. The development of the Tina-quant Lipoprotein (a) Gen.2 J Clin Lipidol.
Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors.
I am excited about the potential of the FAI-Score biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation." Details of the study, included in a written statement issued by Caristo Diagnostics, follow.
Introduction/Background:According to the American Heart Association, the accumulation of plaque in the walls of arteries is identified as the primary cause of atherosclerotic cardiovasculardisease (ASCVD). While hsCRP shows moderate diagnostic accuracy, it is not sufficient as a standalone ASCVD risk diagnostic marker.
BackgroundPatients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovasculardiseases. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 7 Research has shown inflammation plays a significant role in the development of atherosclerosis and ASCVD,8-10 and even the formation of plaque.11 4 In the U.S.
Most of the evidence on the harms of extreme exercise is related to a biomarker of cardiovasculardisease known as coronary artery calcification or CAC. ” Biomarkers of cardiovasculardisease are one thing. ” Biomarkers of cardiovasculardisease are one thing. population.
Coronary artery calcium (CAC) is a measure of atherosclerosis and a strong predictor of cardiovasculardisease. Cross-sectional studies reveal that endurance athletes, particularly middle-aged and older men, often exhibit higher coronary artery calcium scores (CACS) and plaque prevalence compared to less-active individuals.
BackgroundAtherosclerosis is a leading cause of cardiovasculardisease worldwide, while carotid atherosclerosis (CAS) is more likely to cause ischemic cerebrovascular events. Emerging evidence suggests that cuproptosis may be associated with an increased risk of atherosclerotic cardiovasculardisease.
Cardiovasculardisease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovasculardisease in women continues to be underrepresented and undertreated.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content